All articles
Does Mounjaro® Cause Diarrhea? Insights into Side Effects
Reading time:
6 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Diarrhea Risk on Mounjaro® vs other GLP-1 Therapies
The GLP-1 medications are all known to cause diarrhea as a side effect (7). Comparing diarrhea as a side effect between semaglutide (marketed under brand names like Ozempic® and Rybelsus) and tirzepatide (Mounjaro), it is noted that both medications, being part of the GLP-1 receptor agonist family, exhibit gastrointestinal side effects, including diarrhea. However, due to tirzepatide's novel action of engaging GIP receptors, users might experience different gastrointestinal responses. Clinical evidence suggests that while both medications present a risk of diarrhea, the incidence rate and severity may vary from one individual to another, underscoring the importance of personalized medical advice when managing side effects in diabetes treatment.
Managing Side Effects On Your Weight Loss Journey
At Mochi Health, we understand the challenge of weight loss. Having guidance from health professionals can make all the difference in your journey, from managing side effects to maximizing your results. That's why we offer customized support, including GLP-1 prescriptions, from our team of experts. Membership includes virtual visits with a Mochi provider, unlimited appointments with a registered dietitian, access to health screenings, and 24/7 customer support. Curious about brand-name medication prices? They may vary based on your insurance coverage, but Mochi Health offers compounded medications as a reliable and cost-effective solution. Experience the convenience of getting compounded semaglutide at the same low prices for any dose, delivered straight to your doorstep! See if you're eligible for our program and take the first step towards a healthier you today.
References:
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. https://www.nejm.org/doi/10.1056/NEJMoa2206038?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Karrar, H. R., Nouh, M. I., Nouh, Y. I., Nouh, M. I., Khan Alhindi, A. S., Hemeq, Y. H., Aljameeli, A. M., Aljuaid, J. A., Alzahrani, S. J., Alsatami, A. A., Alkredees, M. A., Almuqati, A. O., Abanmi, S. N., & Alshehri, A. M. (2023). Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus, 15(9), e46091. https://www.cureus.com/articles/170540#!/
Kato, S., Sato, T., Fujita, H. et al. Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Sci Rep 11, 9167 (2021). https://www.nature.com/articles/s41598-021-88612-x
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022). Actions of glucagon-like peptide-1 receptor ligands in the gut. British journal of pharmacology, 179(4), 727–742. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15611
Avery, M. E., & Snyder, J. D. (1990). Oral therapy for acute diarrhea. The underused simple solution. The New England journal of medicine, 323(13), 891–894. https://www.nejm.org/doi/10.1056/NEJM199009273231307?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Riddle, M. S., DuPont, H. L., & Connor, B. A. (2016). ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. The American journal of gastroenterology, 111(5), 602–622. https://journals.lww.com/ajg/fulltext/2016/05000/acg_clinical_guideline__diagnosis,_treatment,_and.14.aspx
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of clinical medicine, 12(1), 145. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821052/
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















